{"title":"甲氨蝶呤治疗宫外孕的优点","authors":"Salma Shaik, Lakshmi Manasa Venkata Sai, Kavya Rachamsetty, Dhachinamoorthi Duraiswamy, Rama Chandra Reddy L","doi":"10.26452/fjphs.v4i1.563","DOIUrl":null,"url":null,"abstract":"In recent times there is a shortfall of care about ectopic pregnancy among everyone, inciting conceded finding and potentially non -violent results. Ectopic pregnancy is a very dangerous medical disorder. This occurs when a fertilised egg implants outside of the uterus, generally in the fallopian tube. Making up 5%–10% of all pregnancy-related deaths, ectopic pregnancies are the leading cause of maternal death in the first trimester. Methotrexate is a folic acid inhibitor. It interferes with DNA synthesis and cell multiplication by inhibiting the spontaneous synthesis of purines and pyrimidines. Methotrexate will be used in the middle of six and eight weeks of pregnancy. The likelihood of a future pregnancy succeeding after using methotrexate is generally positive, according to studies. However, a few things could have an impact on these odds. As per to research, ectopic pregnancies are more common among women of reproductive age, usually between the ages of 20 and 35. Given that they are more likely to be sexually active and trying to get pregnant, women in this age range are at their most fertile. Additionally, the prevalence of sexually transmitted diseases (STIs) is higher in this age group, which can mark up the chance of an ectopic pregnancy. Factors affecting ectopic pregnancy risk include previous pelvic surgeries, infections, in vitro fertilization [IVF], endometriosis, smoking, assisted reproductive technologies, and tubal sterilization or previous pregnancies. This review of the literature attempts to shed insight on how methotrexate is currently used to treat ectopic pregnancies","PeriodicalId":503124,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"402 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Virtue of methotrexate in ectopic pregnancy\",\"authors\":\"Salma Shaik, Lakshmi Manasa Venkata Sai, Kavya Rachamsetty, Dhachinamoorthi Duraiswamy, Rama Chandra Reddy L\",\"doi\":\"10.26452/fjphs.v4i1.563\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent times there is a shortfall of care about ectopic pregnancy among everyone, inciting conceded finding and potentially non -violent results. Ectopic pregnancy is a very dangerous medical disorder. This occurs when a fertilised egg implants outside of the uterus, generally in the fallopian tube. Making up 5%–10% of all pregnancy-related deaths, ectopic pregnancies are the leading cause of maternal death in the first trimester. Methotrexate is a folic acid inhibitor. It interferes with DNA synthesis and cell multiplication by inhibiting the spontaneous synthesis of purines and pyrimidines. Methotrexate will be used in the middle of six and eight weeks of pregnancy. The likelihood of a future pregnancy succeeding after using methotrexate is generally positive, according to studies. However, a few things could have an impact on these odds. As per to research, ectopic pregnancies are more common among women of reproductive age, usually between the ages of 20 and 35. Given that they are more likely to be sexually active and trying to get pregnant, women in this age range are at their most fertile. Additionally, the prevalence of sexually transmitted diseases (STIs) is higher in this age group, which can mark up the chance of an ectopic pregnancy. Factors affecting ectopic pregnancy risk include previous pelvic surgeries, infections, in vitro fertilization [IVF], endometriosis, smoking, assisted reproductive technologies, and tubal sterilization or previous pregnancies. This review of the literature attempts to shed insight on how methotrexate is currently used to treat ectopic pregnancies\",\"PeriodicalId\":503124,\"journal\":{\"name\":\"Future Journal of Pharmaceuticals and Health Sciences\",\"volume\":\"402 10\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceuticals and Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26452/fjphs.v4i1.563\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceuticals and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26452/fjphs.v4i1.563","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
近来,每个人都对宫外孕缺乏关注,从而导致了误诊和潜在的非暴力结果。宫外孕是一种非常危险的疾病。当受精卵着床于子宫以外的地方,通常是输卵管时,就会发生宫外孕。宫外孕占所有妊娠相关死亡的 5%-10%,是妊娠头三个月孕产妇死亡的主要原因。甲氨蝶呤是一种叶酸抑制剂。它通过抑制嘌呤和嘧啶的自发合成来干扰 DNA 合成和细胞繁殖。甲氨蝶呤将在怀孕六周和八周中期使用。根据研究,使用甲氨蝶呤后未来成功怀孕的可能性一般是积极的。不过,有几种情况可能会对这种可能性产生影响。根据研究,宫外孕在育龄妇女中更为常见,通常在 20 至 35 岁之间。鉴于她们更有可能性生活活跃并试图怀孕,这个年龄段的女性正处于生育能力最强的时期。此外,这个年龄段的女性性传播疾病(STI)发病率较高,这也会增加宫外孕的几率。影响宫外孕风险的因素包括既往盆腔手术、感染、体外受精(IVF)、子宫内膜异位症、吸烟、辅助生殖技术、输卵管绝育或既往妊娠。本文献综述试图深入探讨目前如何使用甲氨蝶呤治疗异位妊娠
In recent times there is a shortfall of care about ectopic pregnancy among everyone, inciting conceded finding and potentially non -violent results. Ectopic pregnancy is a very dangerous medical disorder. This occurs when a fertilised egg implants outside of the uterus, generally in the fallopian tube. Making up 5%–10% of all pregnancy-related deaths, ectopic pregnancies are the leading cause of maternal death in the first trimester. Methotrexate is a folic acid inhibitor. It interferes with DNA synthesis and cell multiplication by inhibiting the spontaneous synthesis of purines and pyrimidines. Methotrexate will be used in the middle of six and eight weeks of pregnancy. The likelihood of a future pregnancy succeeding after using methotrexate is generally positive, according to studies. However, a few things could have an impact on these odds. As per to research, ectopic pregnancies are more common among women of reproductive age, usually between the ages of 20 and 35. Given that they are more likely to be sexually active and trying to get pregnant, women in this age range are at their most fertile. Additionally, the prevalence of sexually transmitted diseases (STIs) is higher in this age group, which can mark up the chance of an ectopic pregnancy. Factors affecting ectopic pregnancy risk include previous pelvic surgeries, infections, in vitro fertilization [IVF], endometriosis, smoking, assisted reproductive technologies, and tubal sterilization or previous pregnancies. This review of the literature attempts to shed insight on how methotrexate is currently used to treat ectopic pregnancies